RxDoctor Payments Data

Melissa Moore-Colvert, PA

Physician Assistant · Enid, OKNPI 1447555628

Payments from drug & device makers

$3,091in general payments, 2019–2025

Across 147 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$594
  • Philips North America LLC$236
  • Johnson & Johnson$233
  • E.r. Squibb & Sons, L.L.C.$167
  • Teleflex LLC$161
  • Endologix LLC$149
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$3,091100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,091 in reported general payments places this provider in the 85th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$184,400
Medicare patients
882
Services billed
3,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$118,935
EntrestoSacubitril/Valsartan55$51,526
XareltoRivaroxaban48$35,451
FarxigaDapagliflozin Propanediol21$17,508
OzempicSemaglutide12$8,947
JardianceEmpagliflozin11$7,381
Metoprolol Succinate225$2,672
Ranolazine ErRanolazine34$2,505
Rosuvastatin Calcium236$2,232
Losartan Potassium163$1,822
Atorvastatin Calcium126$1,723
Carvedilol219$1,583
Valsartan80$1,470
ClopidogrelClopidogrel Bisulfate96$1,178
Amlodipine Besylate183$1,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$50$118,935158 claims
NovartisEntresto$140$51,52655 claims
Johnson & JohnsonXarelto$233$35,45148 claims
AstraZenecaFarxiga$96$17,50821 claims
Novo NordiskOzempic$27$8,94712 claims
Boehringer IngelheimJardiance$149$7,38111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Enid

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →